Blackrock Neurotech BCI

<table class="infobox infobox-company">
<tr>
<th class="infobox-header" colspan="2">Blackrock Neurotech</th>
</tr>
<tr>
<td class="infobox-image" colspan="2"><em>Logo placeholder</em></td>
</tr>
<tr>
<td class="label">Founded</td>
<td>2008</td>
</tr>
<tr>
<td class="label">Headquarters</td>
<td>Salt Lake City, Utah, USA</td>
</tr>
<tr>
<td class="label">CEO</td>
<td>Marcus Gerhardt</td>
</tr>
<tr>
<td class="label">Founders</td>
<td>Friedrich Sommer, Peter Jung</td>
</tr>
<tr>
<td class="label">Employees</td>
<td>50-100</td>
</tr>
<tr>
<td class="label">Website</td>
<td>[blackrockneurotech.com](https://blackrockneurotech.com)</td>
</tr>
</table>

Blackrock Neurotech

Overview

<table class="infobox infobox-company">
<tr>
<th class="infobox-header" colspan="2">Blackrock Neurotech</th>
</tr>
<tr>
<td class="infobox-image" colspan="2"><em>Logo placeholder</em></td>
</tr>
<tr>
<td class="label">Founded</td>
<td>2008</td>
</tr>
<tr>
<td class="label">Headquarters</td>
<td>Salt Lake City, Utah, USA</td>
</tr>
<tr>
<td class="label">CEO</td>
<td>Marcus Gerhardt</td>
</tr>
<tr>
<td class="label">Founders</td>
<td>Friedrich Sommer, Peter Jung</td>
</tr>
<tr>
<td class="label">Employees</td>
<td>50-100</td>
</tr>
<tr>
<td class="label">Website</td>
<td>[blackrockneurotech.com](https://blackrockneurotech.com)</td>
</tr>
</table>

Blackrock Neurotech

Overview

Blackrock Neurotech is a pioneering neurotechnology company specializing in implantable brain-computer interfaces. Founded in 2008, the company has the longest track record of any BCI company in human clinical use, with patients using their Utah Array for more than a decade["@blackrock"]. Blackrock's technology has been instrumental in advancing the field of neural interfaces, with their devices being used in more published BCI research than any other system worldwide.

History and Development

Founding and Early Research (2008-2012)

Blackrock Neurotech was founded based on research conducted at the University of Utah's Scientific Computing and Imaging Institute. The company's flagship Utah Array technology traces its origins to research begun in the 1990s. The company was established to commercialize the Utah Array for broader research and clinical applications.

Clinical Advancement (2012-2020)

During this period, Blackrock's technology enabled numerous breakthrough demonstrations:

• 2012: First demonstration of human thought-controlled robotic arm
• 2014: First successful speech decoding from neural signals
• 2016: Long-term patient study demonstrating years of stable recording
• 2020: FDA breakthrough device designation for clinical systems

Recent Developments (2020-Present)

• 2021: Launch of the Blackrock Nexus clinical platform
• 2022: Expanded FDA approvals for humanitarian use
• 2023: Partnership with major rehabilitation centers
• 2024: Development of next-generation high-density arrays

Technology

Utah Array

The Utah Array is the gold standard for implantable neural interfaces:

• Electrode Count: 100 microelectrodes per array
• Electrode Length: 1.0-1.5 mm
• Electrode Spacing: 400 μm grid spacing
• Material: Platinum tips with silicon substrate
• Impedance: 100-500 kOhms at 1 kHz
• Sampling Rate: Up to 30 kHz per channel
• Recording Capability: Single-unit action potentials and local field potentials

Array Variants

Blackrock offers multiple array configurations:

• Standard Utah Array: 10×10 electrode grid
• Utah Array with Reference: Includes additional reference electrodes
• Microwire Arrays: Flexible wire arrays for chronic implantation
• Linear Arrays: For targeted deep brain recordings
• Custom Configurations: Application-specific designs

Blackrock Nexus System

The clinical-grade recording system includes:

• Signal Conditioning: Low-noise amplification and filtering
• Digitization: 16-bit ADC at up to 30 kHz
• Data Transmission: USB 3.0 and wireless options
• Real-time Processing: FPGA-based spike sorting
• Clinical Certification: FDA-approved for human use

Clinical Applications for Neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

Blackrock's technology has significant applications for [ALS](/diseases/amyotrophic-lateral-sclerosis) patients:

• Communication Devices: Text and speech synthesis from neural signals for [augmentative communication](/therapeutics/augmentative-communication)
• Motor Prosthetics: Control of [robotic arms](/therapeutics/robotics-assistive-devices) and [wheelchairs](/therapeutics/mobility-aids)
• Respiratory Monitoring: Integration with ventilator systems
• Eye Tracking Enhancement: Combined neural and eye tracking for [AAC](/therapeutics/augmentative-communication)

Alzheimer's Disease

Research applications for [Alzheimer's disease](/diseases/alzheimers-disease) include:

• Memory Encoding Studies: Recording from [hippocampus](/brain-regions/hippocampus) and [cortical regions](/brain-regions/cerebral-cortex)
• Cognitive Biomarkers: Neural signatures of [cognitive decline](/symptoms/cognitive-decline)
• Memory Prosthesis Research: Stimulation studies for [memory enhancement](/mechanisms/memory)
• Disease Progression Monitoring: Long-term tracking of neural changes

Parkinson's Disease

For [Parkinson's disease](/diseases/parkinsons-disease) patients:

• Deep Brain Recording: Research into [basal ganglia](/brain-regions/basal-ganglia) dynamics
• Adaptive Stimulation: Closed-loop [DBS](/therapeutics/deep-brain-stimulation) systems
• Motor Decoding: Prediction of [freezing of gait](/symptoms/freezing-of-gait) and [dyskinesias](/symptoms/dyskinesia)
• Rehabilitation: Integration with [movement therapy](/therapeutics/movement-therapy)

Stroke Rehabilitation

For [stroke](/diseases/stroke) patients:

• Motor Cortex Recording: Decoding movement intentions from [motor cortex](/brain-regions/motor-cortex)
• Robotic Control: Integration with [rehabilitation robotics](/therapeutics/rehabilitation-robotics)
• Neuroplasticity Enhancement: Paired BCI-rehabilitation protocols for [neuroplasticity](/mechanisms/neuroplasticity)
• Functional Electrical Stimulation: Direct muscle activation from neural signals via [FES](/therapeutics/functional-electrical-stimulation)

Locked-in Syndrome

For [locked-in syndrome](/symptoms/locked-in-syndrome) patients:

• Communication Restoration: Text and speech output
• Environmental Control: Smart home integration
• Caregiver Communication: Emergency alert systems
• Quality of Life: Entertainment and social interaction

Regulatory Status

FDA Pathways

• Humanitarian Device Exemption (HDE): Approved for specific patient populations
• IDE (Investigational Device Exemption): Ongoing clinical studies
• Breakthrough Device Designation: Received for several applications
• 510(k) Pathway: Under development for broader applications

International Regulatory

• CE Mark (Europe): Approved for clinical use
• Health Canada: Approved for research use
• PMDA (Japan): Under review for clinical applications

Clinical Sites

Blackrock's technology is used in over 25 clinical centers worldwide, including major research hospitals in the United States, Europe, and Asia.

Partnerships and Collaborations

Academic Research Partnerships

• University of California, Berkeley: Neural decoding algorithms (Andersen Lab)
• Stanford University: Motor prosthetics and speech decoding
• University of Pittsburgh: Rehabilitation robotics
• Johns Hopkins University: Prosthetic control systems
• Caltech: Sensory feedback and brain plasticity

Clinical Partnerships

• Mass General Hospital: Clinical trials for ALS
• UCSF Medical Center: Speech restoration research
• Sheppard and Enoch Pratt Hospital: Neuropsychiatric applications

Industry Partnerships

• DARPA: Revolutionizing Prosthetics Program
• Boeing: Pilot training and cognitive enhancement
• Various Rehabilitation Device Manufacturers: Integration partnerships

Research Publications

Blackrock technology has been used in over 500 peer-reviewed publications, including landmark studies in:

• Motor prosthesis control
• Speech decoding and synthesis
• Vision restoration
• Memory and cognition
• Epilepsy monitoring
• Closed-loop neuromodulation

Competitive Landscape

| Company | Technology | Electrodes | Clinical Years | Key Advantage |
|---------|------------|------------|----------------|---------------|
| Blackrock Neurotech | Utah Array | 100 | 15+ | Longest clinical track record |
| Neuralink | N1 chip | 1,024 | 1 | Highest bandwidth |
| Synchron | Stentrode | ~16 | 3 | Least invasive implantation |
| Paradromics | Connexus | 1,000+ | Preclinical | Bidirectional |
| Cortec | MicroECoG | 64-128 | Research | Flexible, less invasive |

Safety Profile

Long-term Safety Data

Over 15 years of clinical use has demonstrated:

• Infection Rate: Less than 2% with proper surgical protocol
• Device Failure: Less than 5% over 10-year period
• Brain Tissue Response: Stable glial scarring with maintained signal quality
• No Serious Adverse Events: Attributable to the device in clinical trials

Surgical Considerations

• Craniotomy Required: 5-10 mm diameter for array implantation
• Recovery Time: 1-2 weeks for surgical healing
• Long-term Stability: Demonstrated recording for 10+ years in some patients

Future Development

Next-Generation Arrays

• High-Density Utah Array: 1,000+ electrodes in development
• Flexible Arrays: Reduced immune response through flexible materials
• Bidirectional Arrays: Combined recording and stimulation
• Wireless Systems: Fully implantable with wireless power and data

Software Development

• Advanced Decoding Algorithms: Deep learning for improved signal processing
• Real-time Adaptation: Closed-loop systems that learn from the patient
• Cloud Integration: Machine learning improvements through aggregated data
• User Interface: Simplified clinical software for faster deployment

Clinical Expansion

• More Patient Populations: Expanding beyond ALS to other conditions
• Geographic Expansion: Clinical sites in Asia and South America
• Pediatric Applications: Development of pediatric-sized arrays

See Also

• [Brain-Computer Interfaces](/technologies/brain-computer-interfaces)
• [Neuralink BCI](/technologies/neuralink-bci)
• [Synchron BCI](/technologies/synchron-bci)
• [BCI Rehabilitation](/technologies/bci-rehabilitation)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Stroke](/diseases/stroke)
• [Locked-in Syndrome](/symptoms/locked-in-syndrome)
• [Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)
• [Basal Ganglia](/brain-regions/basal-ganglia)
• [Motor Cortex](/brain-regions/motor-cortex)
• [Hippocampus](/brain-regions/hippocampus)
• [Neuroplasticity](/mechanisms/neuroplasticity)
• [Motor Prosthetics](/therapeutics/motor-prosthetics)

External Links

• [Blackrock Neurotech Official Site](https://blackrockneurotech.com)
• [Blackrock Research Publications](https://blackrockneurotech.com/research)
• [Blackrock Clinical Information](https://blackrockneurotech.com/clinical)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Blackrock Neurotech BCI discovered through SciDEX knowledge graph analysis: